RxDoctor Payments Data

Jeffrey Kohn, MD

Cardiovascular Disease · Staten Island, NYNPI 1235218918

Payments from drug & device makers

$871in general payments, 2019–2025

Across 43 payments — averaging $20.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$144
  • Johnson & Johnson$122
  • Amarin Pharma, Inc.$84
  • AbbVie$68
  • Boehringer Ingelheim$66
  • Pfizer$65
  • plus $323 from 11 others

What the payments were for

  • Food & beverage$871100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$871 in reported general payments places this provider in the 35th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$126,964
Medicare patients
350
Services billed
1,402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban61$81,789
XareltoRivaroxaban41$38,056
Repatha SureclickEvolocumab32$17,434
FarxigaDapagliflozin Propanediol11$10,211
MultaqDronedarone Hcl12$9,633
Repatha SyringeEvolocumab11$6,201
Rosuvastatin Calcium251$4,277
Atorvastatin Calcium227$2,572
Metoprolol Succinate138$2,345
Ezetimibe72$2,164
Ranolazine ErRanolazine22$2,016
Nebivolol Hcl34$1,986
Telmisartan49$1,577
Eplerenone22$1,536
Losartan Potassium122$1,425

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$65$81,78961 claims
Johnson & JohnsonXarelto$122$38,05641 claims
Sanofi-aventis U.S. LLCMultaq$22$9,63312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Staten Island

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →